Dexcom's G7 continuous glucose monitor has been shown to enhance blood sugar management in patients with type 2 diabetes who do not use insulin, according to a study presented at the American Diabetes Association. The 26-week trial involved 283 participants, half of whom utilized the G7 device while the other half relied on traditional self-monitoring methods. Those using the G7 experienced an average blood sugar reduction of 1.6%, which is 0.9% greater than the control group. The study also highlighted that combining the G7 with common diabetes medications, such as metformin and GLP-1s, led to further improvements in blood sugar levels. Notably, participants on GLP-1 drugs using the G7 saw a 1.4% decrease in their blood sugar compared to just 0.2% in the control group. Dexcom's CEO, Jake Leach, emphasized the study's implications for establishing a new standard of care for diabetes management, which could lead to increased access to continuous glucose monitoring for all type 2 diabetes patients. A six-month extension of the study is currently underway to gather additional data.